- Home
- MFH vs CAPR Comparison
MFH vs CAPR Comparison
Compare MFH & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- CAPR
- Stock Information
- Founded
- MFH 2011
- CAPR 2005
- Country
- MFH United States
- CAPR United States
- Employees
- MFH N/A
- CAPR N/A
- Industry
- MFH Finance: Consumer Services
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFH Finance
- CAPR Health Care
- Exchange
- MFH Nasdaq
- CAPR Nasdaq
- Market Cap
- MFH 386.1M
- CAPR 324.6M
- IPO Year
- MFH N/A
- CAPR N/A
- Fundamental
- Price
- MFH $9.87
- CAPR $6.40
- Analyst Decision
- MFH
- CAPR Strong Buy
- Analyst Count
- MFH 0
- CAPR 8
- Target Price
- MFH N/A
- CAPR $24.75
- AVG Volume (30 Days)
- MFH 185.6K
- CAPR 1.1M
- Earning Date
- MFH 04-30-2025
- CAPR 11-12-2025
- Dividend Yield
- MFH N/A
- CAPR N/A
- EPS Growth
- MFH N/A
- CAPR N/A
- EPS
- MFH N/A
- CAPR N/A
- Revenue
- MFH N/A
- CAPR $13,392,150.00
- Revenue This Year
- MFH N/A
- CAPR N/A
- Revenue Next Year
- MFH N/A
- CAPR $7,894.07
- P/E Ratio
- MFH N/A
- CAPR N/A
- Revenue Growth
- MFH 125.92
- CAPR N/A
- 52 Week Low
- MFH $1.03
- CAPR $4.92
- 52 Week High
- MFH $10.67
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- MFH 71.56
- CAPR 45.30
- Support Level
- MFH $5.24
- CAPR $6.04
- Resistance Level
- MFH $10.67
- CAPR $6.57
- Average True Range (ATR)
- MFH 1.07
- CAPR 0.39
- MACD
- MFH 0.33
- CAPR 0.05
- Stochastic Oscillator
- MFH 85.17
- CAPR 66.06
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.